Is Rivaroxaban Safe in Patients With Renal Dysfunction?

Affiliations

Editorial

Eun-Sun Jin. Korean Circ J. 2025 Feb.

. 2025 Feb;55(2):132-133.

doi: 10.4070/kcj.2024.0361. Epub 2024 Nov 20.

¹ Cardiovascular Center, Kyung Hee University Hospital at Gangdong, Seoul, Korea. esjin@khu.ac.kr.

No abstract available

Conflict of interest statement

The author has no financial conflicts of interest.

A Real-World, Prospective, Observational Study of Rivaroxaban on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-Valvular Atrial Fibrillation: XARENAL.
Oh IY, Lee CH, Choi EK, Lim HE, Oh YS, Choi JI, Ahn MS, Kim JY, Kim NH, Yoon N, Sandmann M, Choi KJ. Oh IY, et al. Korean Circ J. 2025 Feb;55(2):121-131. doi: 10.4070/kcj.2024.0154. Epub 2024 Oct 23. Korean Circ J. 2025. PMID: 39601397 Free PMC article.

1. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891. - PubMed
1. Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) Eur Heart J. 2024;45:3314–3414. - PubMed
1. Oh IY, Choi KJ, Lee CH, et al. A real-world, prospective, observational study of rivaroxaban on prevention of stroke and non-central nervous systemic embolism in renally impaired Korean patients with non-valvular atrial fibrillation: XARENAL. Korean Circ J. 2025;55:121–131. - PMC - PubMed
1. Yu HT, Yang PS, Kim TH, et al. Impact of renal function on outcomes with edoxaban in real-world patients with atrial fibrillation. Stroke. 2018;49:2421–2429. - PubMed
1. Shin JI, Secora A, Alexander GC, et al. Risks and benefits of direct oral anticoagulants across the spectrum of GFR among incident and prevalent patients with atrial fibrillation. Clin J Am Soc Nephrol. 2018;13:1144–1152. - PMC - PubMed